STEREOTAXIS INC (STXS)
Health Care · Robotic-assisted interventional medical devices · Nyse Mkt Llc
Stereotaxis develops robotic magnetic navigation systems for minimally invasive interventional procedures in cardiology, electrophysiology, and vascular interventions.
What STEREOTAXIS INC does
Stereotaxis designs, manufactures, and markets robotic magnetic navigation systems that enable physicians to perform minimally invasive interventional procedures with greater precision and efficiency. The company's primary product is the Niobe robotic magnetic navigation system, which guides catheters and medical devices through the body using computer-controlled magnetic fields. The company generates revenue from systems sales, as well as from disposables, services, and accessories that support ongoing clinical use. Stereotaxis operates globally, with a focus on hospitals and interventional centers performing cardiac electrophysiology, cardiology, and vascular procedures.
Themes: ["Robotic minimally invasive surgery","Interventional cardiology","Cardiac electrophysiology","Medical device innovation","Catheter-based interventions","Precision guidance systems"]
Fundamentals
- Price$1.74 as of 2026-07-09 close
- Market cap$172M as of 2026-07-10
- 1-year return-21.3% as of 2026-07-09 close
- Net margin-69.5% as of 2026-07-10
- Gross margin+53.9% as of 2026-07-10
- ROE-153.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+13.4% as of 2026-07-10
- Revenue CAGR (3y)+4.8% SEC XBRL
- Beta1.42 as of 2026-07-10
Key risks (from latest filing)
["The company has not achieved profitability, with a net margin of -69.5% as of July 2026, and may struggle to generate sufficient cash from operations to fund ongoing business activities and product development.","Hospital decision-makers may view Stereotaxis systems as too expensive relative to competing alternatives, and long, variable sales cycles create substantial quarterly revenue volatility that makes financial forecasting difficult.","Reliance on contract manufacturers and, in some cases, single suppliers for key components (particularly overseas sourcing of magnet materials) creates supply chain vulnerability and potential manufacturing delays that could harm revenue and competitiveness."]
Competitors & peers
- Abbott (ABT)
- Boston Scientific (BSX)
- Medtronic (MDT)
- Siemens Healthineers (SIEM)
- Koninklijke Philips (PHG)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.